In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving ...

The trial’s primary objective is to assess PALI-2108’s tolerability, pharmacokinetics and safety in healthy volunteers.